Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004009 | PO / MO |
Both patients took all four capsules of the Vivotif at one time; Both patients took all four capsules of the Vivotif at one time; Case reference number US-BN-2024-001825 is a spontaneous case report initially received from pharmacist via Med Communication (reference number: USBAV24-0755) on 16-Apr-2024 and concerns *64-year-old female patient and 65-year-old male patient (multi 2).* The patients relevant medical history and concomitant medications were not provided. *On 12-Apr-2024, two patients were vaccinated with all four doses of Vivotif (batch number: 3004009, expiry date: Oct-2024), at a dose of four capsules*, orally, for typhoid immunization (explicitly coded as 'vaccine overdose' and 'inappropriate schedule of vaccine administered'). *At the time of follow up report, the patients did not experience any adverse event due to Vivotif vaccine*. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up report received from a pharmacist on 16-May-2024: New information included patients demographic details (age, gender and initials), Vivotif dosage information, confirmation that the patients did not experience any adverse events.; Reporter's Comments: This case concerns 64-year-old female patient and 65-year-old male patient who were vaccinated with all four doses of Vivotif for typhoid immunization, which is considered as vaccine overdose and inappropriate schedule of vaccine administered. No associated adverse events were reported. Overdose and inappropriate schedule of product administration are listed per company convention. The patients' relevant medical history and concomitant medications were not provided. Overdose and inappropriate schedule of vaccine administered are not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: This case concerns 64-year-old female patient and 65-year-old male patient who were vaccinated with all four doses of Vivotif for typhoid immunization, which is considered as vaccine overdose and inappropriate schedule of vaccine administered. No associated adverse events were reported. Overdose and inappropriate schedule of product administration are listed per company convention. The patients' relevant medical history and concomitant medications were not provided. Overdose and inappropriate schedule of vaccine administered are not related to Vivotif, but to a human factor. The case is non-serious.
Comments: None.